Gonadotropin-releasing hormone (GnRH) receptor agonists are extensively used in the treatment of sex hormone-dependent cancers via the desensitization of pituitary gonadotropes and consequent decrease in steroid sex hormone secretion. However, evidence now points to a direct inhibitory effect of GnRH analogs on cancer cells. These effects appear to be mediated via the Galpha(i)-type G protein, ...

Osteochondritis dissecans (OCD) is a chronic disease of the articular cartilage characterized by focal lesions subchondral bone and overlaying cartilage. Through growing number reports describing high prevalence OCD in some families, subcategory termed familial (FOCD) was established. With development genetic approaches such as genome-wide association studies sequencing, aggrecan (ACAN) has bee...

In the twentieth century, a whole teaching of mastopathy was formed. However, over time, accumulated data have questioned existence as separate nosological form, because term “fibrocystic disease” while mastalgia is most common symptom does not correspond to holistic concept disease. This “disease” can be diagnosed in any woman and more or less successfully treated. United States, this obsolete...

To study the luteinizing hormone-releasing hormone (LH-RH; luliberin) receptors in the rat anterior pituitary gland and ovary, 125I-labeled [D-Ser(TBU)6des-Gly-NH2(10)]LH-RH ethylamide was used as a labeled ligand. The binding characteristics were assessed by Scatchard analysis of labeled ligand binding and by potency displacement with unlabeled peptides. Similar Kd values, ranging from 0.1 to ...

Methods: Five beagle bitches were administered MPA subcutaneously at 10 mg/kg, every four weeks. A combination of corticotropin-releasing hormone (CRH), growth hormone-releasing hormone (GHRH), gonadotrophin-releasing hormone (GnRH), and thyrotropin-releasing hormone (TRH) was administered before and 2, 5, 8, and 11 months after the initial MPA treatment. Blood samples for determination of plas...